Related Experiment Video

Updated: Oct 2, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Catalytic oligonucleotides targeting EGR-1 as potential inhibitors of in-stent restenosis

L M Khachigian1

  • 1Centre for Thrombosis and Vascular Research, The University of New South Wales, Sydney, Australia. L.Khachigian@unsw.edu.au

Annals of the New York Academy of Sciences
|January 25, 2002
PubMed

Insights

Researchers explored catalytic DNA strategies to target the Egr-1 transcription factor, aiming to prevent restenosis after angioplasty. This approach shows promise for inhibiting artery narrowing post-procedure.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Gene Regulation

Background:

  • Postangioplasty restenosis remains a significant clinical challenge.
  • The transcription factor Early Growth Response-1 (Egr-1) plays a crucial role in vascular smooth muscle cell proliferation and migration, key processes in restenosis.
  • Current therapeutic strategies have limitations in effectively preventing restenosis.

Purpose of the Study:

  • To review and discuss recent advancements in targeting Egr-1 using catalytic DNA (DNAzymes).
  • To evaluate the potential of these catalytic DNA strategies in inhibiting postangioplasty restenosis.

Main Methods:

  • Literature review of studies employing catalytic DNA to target Egr-1.
  • Analysis of mechanisms by which Egr-1 contributes to restenosis.
  • Examination of DNAzyme design and delivery for therapeutic applications.

Main Results:

  • Catalytic DNA can be designed to specifically inhibit Egr-1 gene expression or protein activity.
  • Inhibition of Egr-1 has demonstrated efficacy in preclinical models of vascular restenosis.
  • These strategies offer a novel approach to gene silencing in the context of cardiovascular disease.

Conclusions:

  • Targeting Egr-1 with catalytic DNA represents a promising therapeutic strategy for preventing postangioplasty restenosis.
  • Further research and development are warranted to translate these findings into clinical practice.
  • Catalytic DNA offers a precise and potentially potent method for modulating gene expression in cardiovascular interventions.

More Related Videos

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...